Skip to content


Medicines Transparency Alliance (MeTA)

Itad carried out an evaluation of the Medicines Transparency Alliance (MeTA). MeTA was a DFID-funded initiative, coordinated by Health Action International (HAI) and the World Health Organisation (WHO), and implemented in seven pilot countries (Ghana, Jordan, Kyrgyzstan, Peru, the Philippines, Uganda and Zambia) from 2008.


The aim of the initiative was to improve access to essential medicines. MeTA focussed on promoting evidence-based policymaking in the medicines sector through two key strategies: 1) Transparency, by supporting the collection, analysis and dissemination of medicines supply chain data; and 2) Accountability, by promoting multi-stakeholder dialogue between government, the private sector and civil society.

The aim of the evaluation

The purpose of the MeTA evaluation was to determine whether improved transparency, accountability and quality multi-stakeholder collaboration increases evidence-based policymaking and thereby the accessibility of essential medicines.

Our approach

To better understand this, the evaluation team identified where new and/or improved access to medicines policies existed within each MeTA country, explored how this change had come about and whether MeTA had contributed to it. A rigorous theory-based evaluation methodology was employed, combining Qualitative Comparative Analysis (QCA) with elements of Contribution Analysis. The evaluation started in August 2014 and was completed in January 2016.

Read the blog.

Read the Policy Briefing.

Read the final report.


Contact Sam McPherson ( if you would like to discuss this project.

Image © Kpando Medical Clinical 141. Photo credit: Nora Morgan
Team members